Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type‐2 diabetes-Reference-Cited by-同舟云学术

Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type‐2 diabetes

Published:2019-06-17 Issue:9 Volume:21 Page:2096-2106
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Garry Elizabeth M.¹²^ORCID,Buse John B.³,Gokhale Mugdha¹⁴^ORCID,Lund Jennifer L.¹,Nielsen Matthew E.¹⁵,Pate Virginia¹,Stürmer Til¹

Affiliation:

1. Department of EpidemiologyUniversity of North Carolina at Chapel Hill Chapel Hill North Carolina

2. Science, Aetion Inc. Boston Massachusetts

3. Department of MedicineUniversity of North Carolina School of Medicine Chapel Hill North Carolina

4. Real World Evidence and Epidemiology, GlaxoSmithKline Collegeville, Pennsylvania

5. Urologic OncologyUniversity of North Carolina School of Medicine Chapel Hill North Carolina

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13774

Reference45 articles.

1. Health care utilization among U.S. adults with diagnosed diabetes, 2013;Villarroel MA;NCHS Data Brief,2015

2. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

3. Federal Drug Administration. (2007).MedWatch safety alerts for human medical products: 2007 safety alerts for human medical products. Retrieved fromhttp://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm. Accessed September 2013.

4. Federal Drug Administration. (2011).Actos (pioglitazone): ongoing safety review ‐ potential increased risk of bladder cancer. medwatch safety alerts for human medical products: 2011 safety alerts for human medical products. Retrieved fromhttps://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed September 2013.

5. Federal Drug Administration. (2016).FDA Drug Safety Communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. Retrieved fromhttp://www.fda.gov/Drugs/DrugSafety/ucm519616.htm. Accessed December 12 2016.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pioglitazone, Bladder Cancer, and the Presumption of Innocence;Current Drug Safety;2022-11

2. Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions;Diabetes Spectrum;2022-11-01

3. Careful use to minimize adverse events of oral antidiabetic medications in the elderly;Expert Opinion on Pharmacotherapy;2021-04-13

4. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments;Endocrine Reviews;2021-03-12

5. Transparency in real‐world evidence (RWE) studies to build confidence for decision‐making: Reporting RWE research in diabetes;Diabetes, Obesity and Metabolism;2020-04